Decoy Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Decoy Therapeutics Inc. (DCOY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 123.31% for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2024-05-13
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 123.31%.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-03-31 was 113.17%.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2019 was 103.70%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2024-03-31 | 123.31% 10-Q · filed 2024-05-13 | |||
| 2022-01-20 | 125.19% 10-Q · filed 2022-05-12 | |||
| 2021-09-02 | 130.44% 10-Q · filed 2021-11-04 | |||
| 2021-06-16 | 131.06% 10-Q · filed 2021-11-04 | |||
| 2021-03-10 | 133.35% 10-Q · filed 2022-05-12 | |||
| 2020-09-16 | 125.42% 10-Q · filed 2020-11-12 | |||
| 2020-07-14 | 124.20% 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 113.17% 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | 113.17% 10-Q/A · filed 2020-05-15 | |||
| 2020-03-23 | 113.17% 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | 103.70% 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |